All In Biotech

Drug Trial Radar · NCT05115110

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

97

Actual

Start

Jun 2, 2022

Primary completion

Nov 2, 2026

Study completion Nov 2, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Risdiplam works by helping the body produce more survival motor neuron (SMN) protein throughout the body. This means fewer motor neurons - nerve cells that pass impulses from nerves to muscles to cause movement - are lost, which may improve how well muscles work in people with SMA. RO7204239 is an investigational anti-myostatin antibody that is designed to target myostatin. Myostatin plays an important role in the regulation of skeletal muscle size by controlling growth. Inhibiting myostatin may help muscles grow in size and strength. RO7204239 in combination with risdiplam, which is designed to increase the amount of SMN protein throughout the body, has the potential to further improve motor function and clinical outcomes for people living with SMA. This trial will study the safety and efficacy of RO7204239 in combination with risdiplam in patients with spinal muscular atrophy (SMA). The trial has two parts; Part 1 is the dose-finding part in SMA patients that are either ambulant (aged 2-10 years) or non-ambulant (aged 5-10 years) within separate cohorts, and Part 2 is the pivotal part in SMA patients aged 2-25 years that are ambulant.

Conditions

  • Spinal Muscular Atrophy (SMA)

Interventions

  • RO7204239Drug

    RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen. RO7204239 will be investigated at low- and high-dose in Part 1.

  • PlaceboDrug

    Placebo will be administered Q4W by SC injection into the abdomen.

  • RisdiplamDrug

    Risdiplam will be administered orally once daily (QD) for the duration of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Percentage of participants with adverse events (AEs)Time frame: Up to 4.5 years
  2. Part 1 - Incidence of relevant echocardiographic parameter z scores > 2Time frame: Up to 4.5 years
  3. Part 1 - Serum concentration of RO7204239Time frame: Through Week 96
  4. Part 1 - Time to maximum serum concentration (Cmax) of RO7204239Time frame: Through Week 96
  5. Part 1 - Area under the curve (AUC) of RO7204239Time frame: Through Week 96
  6. Part 1 - Trough concentration (Ctrough) of RO7204239Time frame: Through Week 96
  7. Part 1 - Plasma concentration of risdiplamTime frame: Week 21
  8. Part 1 - Plasma concentration of risdiplam metabolite (M1)Time frame: Week 21
  9. Part 1 - Cmax of risdiplamTime frame: Week 21
  10. Part 1 - AUC of risdiplamTime frame: Week 21
  11. Part 1 - Ctrough of risdiplamTime frame: Week 21
  12. Part 1 - Incidence of anti-drug antibodies (ADAs)Time frame: Through Week 96
  13. Part 1 - Change from baseline in serum concentration of total myostatinTime frame: Through Week 85
  14. Part 1 - Change from baseline in serum concentration of free latent myostatinTime frame: Through Week 85
  15. Part 1 - Change from baseline in serum concentration of mature myostatinTime frame: Through Week 85
  16. Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant thigh muscles as assessed by magnetic resonance imaging (MRI) in participants aged at least 5 yearsTime frame: Week 24 of combination treatment
  17. Part 1 - Percent change from baseline in the contractile area of skeletal muscle in the dominant calf muscles as assessed by MRI in participants aged at least 5 yearsTime frame: Week 24 of combination treatment
  18. Part 2 - Change from baseline in Revised Hammersmith Scale (RHS) total scoreTime frame: Week 72 of combination treatment (study Week 80)

Locations

29 sites in 12 countries. Site status is shown where the registry gives one.

  • Boston Childrens Hospital

    Boston, Massachusetts

  • Columbia University Medical Center

    New York, New York

  • Sydney Children's Hospital

    Randwick, New South Wales, Australia

  • UZ Gent

    Ghent, Belgium

  • Chr de La Citadelle

    Liège, Belgium

  • British Columbia Children's Hospital

    Vancouver, British Columbia, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, Canada

  • Clinical Hospital Centre Zagreb

    Zagreb, Croatia

  • Policlinico Agostino Gemelli

    Rome, Lazio, Italy

  • Fondazione IRCCS Istituto Neurologico ?Carlo Besta?

    Milan, Lombardy, Italy

  • Asst Grande Ospedale Metropolitano Niguarda

    Milan, Lombardy, Italy

  • Ospedali Riuniti Torrette di Ancona

    Ancona, The Marches, Italy

  • Kobe University Hospital

    Hyōgo, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • National Center for Global Health and Medicine

    Shinjuku-ku, Japan

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Instytut Centrum Zdrowia Matki Polki

    ?ód?, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland

  • Uniwersytecki Szpital Kliniczny w Poznaniu

    Późna, Poland

  • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie

    Warsaw, Poland

  • Instytut Pomnik Centrum Zdrowia Dziecka

    Warsaw, Poland

  • CHULC, E.P.E. - Hospital Dona Estefania

    Lisbon, Portugal

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario la Fe

    Valencia, Spain

  • Hospital Sant Joan De Deu

    Esplugues de Llobregas, Barcelona, Spain

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom

  • John Radcliffe Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.